Neuroendocrine Carcinoma — Trials

Neuroendocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,533 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 514
Recruiting: 261
Ph III recruiting: 29
Growth YoY: +4.2%
Industry share: 38%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (213)

clinicaltrialsPublishedShowing 51–53 of 53 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03212404	Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers	active not recruiting	Phase 1	272	Checkpoint Therapeutics, Inc.INDUSTRY	9	Feb 3, 2025	clinicaltrials
NCT05199272	A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies	active not recruiting	Phase 1 / Phase 2	141	23andMe, Inc.INDUSTRY	2	Nov 15, 2024	clinicaltrials